ROIV Stock Analysis: Roivant Sciences | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 24.689m USD | 12M Return: 221.3% | BMG762791017 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 228M
Qual. Beats: 0
Rev. Trend: -96.6%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 5.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Roivant Sciences Ltd. (NASDAQ: ROIV) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in London, UK, that focuses on discovering, developing, and commercializing medicines. Its pipeline includes IMVT-1402, a monoclonal antibody targeting FcRn for IgG-mediated autoimmune indications; mosliciguat, its lead inhaled sGC activator for pulmonary hypertension associated with interstitial lung disease; batoclimab for thyroid eye disease; and brepocitinib, a TYK2/JAK1 inhibitor being studied in immune-mediated diseases such as dermatomyositis and non-infectious uveitis. The company also operates drug delivery platforms, including lipid nanoparticle (LNP) and ligand conjugate technologies.
As a clinical-stage biopharma, Roivant does not yet generate commercial product revenue and depends on capital markets to fund its R&D activities. The biotechnology sector is characterized by long development timelines, high clinical trial failure rates, and significant regulatory risk, with valuation typically driven by pipeline progress, partnership agreements, and milestone-based catalysts rather than current sales.
- Mosliciguat Phase 3 pulmonary hypertension data readout expected
- IMVT-1402 competes with Vyvgart in FcRn autoimmune space
- Cash burn and pipeline funding shape capital allocation strategy
| Net Income: -266.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.15 > 0.02 and ΔFCF/TA 1.72 > 1.0 |
| NWC/Revenue: 59.2k% < 20% (prev 19.4k%; Δ 39.8k% < -1%) |
| CFO/TA -0.15 > 3% & CFO -809.4m > Net Income -266.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 16.72 > 1.5 & < 3 |
| Outstanding Shares: last quarter (720.8m) vs 12m ago 5.95% < -2% |
| Gross Margin: 81.21% > 18% (prev 96.33%; Δ -15.12% > 0.5%) |
| Asset Turnover: 0.15% > 50% (prev 0.46%; Δ -0.32% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.84 (Total Current Assets 4.74b - Total Current Liabilities 283.6m) / Total Assets 5.31b |
| B: -0.17 (Retained Earnings -900.4m / Total Assets 5.31b) |
| C: -0.06 (EBIT TTM -289.9m / Avg Total Assets 5.17b) |
| D: 11.00 (Book Value of Equity 4.23b / Total Liabilities 384.6m) |
| Altman-Z'' = 16.13 = AAA |
As of September 09, 2026, the stock is trading at USD 41.48 with a total of 24,595,112 shares traded. Over the past week, the price has changed by +19.75%, over one month by +15.93%, over three months by +45.59% and over the past year by +221.30%.
Current recommended Stop Loss: 40.00 (which is 3.6% or 1.2 ATR below the current price).
Roivant Sciences has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy ROIV.
- StrongBuy: 6
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 42 | 1.1% |
P/S = 3299.9382
P/B = 5.8929
Revenue TTM = 7.53m USD
EBIT TTM = -289.9m USD
EBITDA TTM = -281.3m USD
Long Term Debt = 94.8m USD (estimated: total debt 107.2m - short term 12.4m)
Short Term Debt = 12.4m USD (from shortTermDebt, last quarter)
Debt = 107.2m USD (from shortLongTermDebtTotal, last quarter) (leases 107.2m already included)
Net Debt = -3.73b USD (calculated: Debt 107.2m - CCE 3.84b)
Enterprise Value = 21.0b USD (24.7b + Debt 107.2m - CCE 3.84b)
Interest Coverage Ratio = unknown (Ebit TTM -289.9m / Interest Expense TTM 0.0)
EV/FCF = -25.74x (Enterprise Value 21.0b / FCF TTM -814.0m)
FCF Yield = -3.88% (FCF TTM -814.0m / Enterprise Value 21.0b)
FCF Margin = -10.8k% (FCF TTM -814.0m / Revenue TTM 7.53m)
Net Margin = -3.53k% (Net Income TTM -266.2m / Revenue TTM 7.53m)
Gross Margin = 81.21% ((Revenue TTM 7.53m - Cost of Revenue TTM 1.42m) / Revenue TTM)
Gross Margin QoQ = 80.31% (prev 87.30%)
Tobins Q-Ratio = 3.95 (Enterprise Value 21.0b / Total Assets 5.31b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 107.2m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -229.0m (EBIT -289.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 16.72 (Total Current Assets 4.74b / Total Current Liabilities 283.6m)
Debt / Equity = 0.03 (Debt 107.2m / totalStockholderEquity, last quarter 4.23b)
Debt / EBITDA = 13.28 (negative EBITDA) (Net Debt -3.73b / EBITDA -281.3m)
Debt / FCF = 4.59 (negative FCF - burning cash) (Net Debt -3.73b / FCF TTM -814.0m)
Total Stockholder Equity = 4.35b (last 4 quarters mean from totalStockholderEquity)
RoA = -5.15% (Net Income -266.2m / Total Assets 5.31b)
RoE = -6.12% (Net Income TTM -266.2m / Total Stockholder Equity 4.35b)
RoCE = -6.53% (EBIT -289.9m / Capital Employed (Equity 4.35b + L.T.Debt 94.8m))
RoIC = -4.55% (negative operating profit) (NOPAT -229.0m / Invested Capital 5.03b)
WACC = 7.68% (E(24.7b)/V(24.8b) * Re(7.71%) + D(107.2m)/V(24.8b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 7.71% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -21.96 | Cagr: -4.68%
[DCF] Fair Price = unknown (Cash Flow -814.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: -96.60 | Revenue CAGR: -58.53% | SUE: -0.02 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.45 | Chg30d=-13.59% | Revisions=-50% | Analysts=3
EPS next Quarter (2026-12-31): EPS=-0.41 | Chg30d=-13.04% | Revisions=-25% | Analysts=3
EPS current Year (2027-03-31): EPS=-1.58 | Chg30d=-5.66% | Revisions=-25% | GrowthEPS=-46.7% | GrowthRev=+518.0%
EPS next Year (2028-03-31): EPS=-1.72 | Chg30d=-10.15% | Revisions=-50% | GrowthEPS=-8.7% | GrowthRev=+676.9%
[Analyst] Revisions Ratio: -73% (up=0, down=8)